Erste Asset Management’s Sangamo Therapeutics SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-38,000
| Closed | -$15.1K | – | 820 |
|
|
2024
Q2 | $15.1K | Hold |
38,000
| – | – | ﹤0.01% | 529 |
|
|
2024
Q1 | $23.7K | Hold |
38,000
| – | – | ﹤0.01% | 520 |
|
|
2023
Q4 | $22.8K | Hold |
38,000
| – | – | ﹤0.01% | 531 |
|
|
2023
Q3 | $21.9K | Hold |
38,000
| – | – | ﹤0.01% | 530 |
|
|
2023
Q2 | $47.5K | Hold |
38,000
| – | – | ﹤0.01% | 539 |
|
|
2023
Q1 | $64.6K | Hold |
38,000
| – | – | ﹤0.01% | 540 |
|
|
2022
Q4 | $118K | Hold |
38,000
| – | – | ﹤0.01% | 528 |
|
|
2022
Q3 | $185K | Hold |
38,000
| – | – | ﹤0.01% | 499 |
|
|
2022
Q2 | $157K | Hold |
38,000
| – | – | ﹤0.01% | 524 |
|
|
2022
Q1 | $225K | Hold |
38,000
| – | – | ﹤0.01% | 497 |
|
|
2021
Q4 | $301K | Hold |
38,000
| – | – | 0.01% | 472 |
|
|
2021
Q3 | $347K | Hold |
38,000
| – | – | 0.01% | 448 |
|
|
2021
Q2 | $445K | Hold |
38,000
| – | – | 0.01% | 428 |
|
|
2021
Q1 | $443K | Hold |
38,000
| – | – | 0.01% | 393 |
|
|
2020
Q4 | $632K | Buy |
38,000
+2,000
| +6% | +$33.3K | 0.02% | 368 |
|
|
2020
Q3 | $356K | Hold |
36,000
| – | – | 0.01% | 372 |
|
|
2020
Q2 | $316K | Hold |
36,000
| – | – | 0.01% | 363 |
|
|
2020
Q1 | $234K | Hold |
36,000
| – | – | 0.01% | 342 |
|
|
2019
Q4 | $301K | Hold |
36,000
| – | – | 0.01% | 346 |
|
|
2019
Q3 | $331K | Hold |
36,000
| – | – | 0.02% | 345 |
|
|
2019
Q2 | $380K | Hold |
36,000
| – | – | 0.02% | 335 |
|
|
2019
Q1 | $336K | Hold |
36,000
| – | – | 0.02% | 329 |
|
|
2018
Q4 | $381K | Buy |
+36,000
| New | +$381K | 0.03% | 326 |
|